Cell Centre

Robust cell line development is seen by many as intensive and time-consuming, but it is key to process optimisation, particularly for recombinant therapeutic antibodies – ensuring stable production and lowering product costs

Louis Boon, Bioceros BV (December 2013)

Keywords: Recombinant proteins, Chinese hamster ovary (CHO) cell lines, Metabolic selection, Biosimilar monoclonal antibodies (mAbs), Cost of goods (CoGs)

View full article    |    Back to Biopharma section